We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-5.4%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$111M
AUM Growth
-$3.2M
Cap. Flow
+$4.3M
Cap. Flow %
3.86%
Top 10 Hldgs %
57.45%
Holding
59
New
25
Increased
8
Reduced
9
Closed
16

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12.1M
2
TMO icon
Thermo Fisher Scientific
TMO
+$7.38M
3
BRKR icon
Bruker
BRKR
+$6.46M
4
AVTR icon
Avantor
AVTR
+$4.83M
5
CNMD icon
CONMED
CNMD
+$4.82M

Top Sells

Rank Stock Value
1
LH icon
Labcorp
LH
+$7.86M
2
CI icon
Cigna
CI
+$5.63M
3
A icon
Agilent Technologies
A
+$5.5M
4
BDX icon
Becton Dickinson
BDX
+$3.53M
5
IQV icon
IQVIA
IQV
+$3.31M

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Real Estate 4.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PODD icon
26
Insulet
PODD
$9.43B
$1.42M 1.27%
+8,878
New +$1.99M
ETNB
27
DELISTED
89bio
ETNB
$1.27M 1.14%
82,153
+52,871
+181% +$888K
HOLX
28
DELISTED
Hologic
HOLX
$1.23M 1.11%
+17,750
New +$1.34M
OCUL icon
29
Ocular Therapeutix
OCUL
$1.9B
$1.11M 1%
353,707
-14,731
-4% -$60.3K
AZTA icon
30
Azenta
AZTA
$1.42B
$975K 0.88%
+19,422
New +$976K
TARS icon
31
Tarsus Pharmaceuticals
TARS
$2.83B
$847K 0.76%
+47,649
New +$843K
AHCO icon
32
AdaptHealth
AHCO
$843M
$818K 0.74%
+89,937
New +$1.08M
AXSM icon
33
Axsome Therapeutics
AXSM
$11B
$787K 0.71%
+11,254
New +$841K
IQV icon
34
IQVIA
IQV
$37.9B
$776K 0.7%
3,946
-15,223
-79% -$3.31M
BLUE
35
DELISTED
bluebird bio
BLUE
$765K 0.69%
12,589
-1,483
-11% -$104K
OLMA icon
36
Olema Pharmaceuticals
OLMA
$1.03B
$723K 0.65%
58,573
+18,389
+46% +$187K
VTYX
37
DELISTED
Ventyx Biosciences
VTYX
$641K 0.58%
+18,458
New +$638K
ACLX
38
DELISTED
Arcellx
ACLX
$508K 0.46%
+14,158
New +$488K
GDRX icon
39
GoodRx Holdings
GDRX
$1.28B
$491K 0.44%
+87,290
New +$582K
RNAC icon
40
Cartesian Therapeutics
RNAC
$255M
$481K 0.43%
15,110
-7,761
-34% -$259K
TLT icon
41
iShares 20+ Year Treasury Bond ETF
TLT
$41.7B
$302K 0.27%
+3,400
New +$327K
NVST icon
42
Envista
NVST
$4.62B
$301K 0.27%
+10,787
New +$349K
ADAP
43
DELISTED
Adaptimmune Therapeutics
ADAP
$243K 0.22%
311,944
-509,094
-62% -$427K
A icon
44
Agilent Technologies
A
$39.4B
– –
-45,762
Closed -$5.5M
ACHC icon
45
Acadia Healthcare
ACHC
$2.9B
– –
-9,153
Closed -$729K
BDX icon
46
Becton Dickinson
BDX
$49B
– –
-13,360
Closed -$3.53M
BMRN icon
47
CALL
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-93,600
Closed -$8.11M
BTAI icon
48
CALL
BioXcel Therapeutics
BTAI
$25.7M
– –
-3,569
Closed -$380K
CAH icon
49
Cardinal Health
CAH
$54.9B
– –
-31,696
Closed -$3M
EHC icon
50
Encompass Health
EHC
$12.3B
– –
-32,710
Closed -$2.21M
1
2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Endurant Capital Management held 59 positions worth $111M, down 2.8% from $115M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Endurant Capital Management deployed $4.3M of net new capital in Q3 2023, opening 25 new positions and adding to 8 existing holdings. Its largest new stake was Thermo Fisher Scientific: 13,849 shares worth $7.01M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 66% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Cigna, an estimated $5.63M trimmed.

  • Endurant Capital Management's largest Q3 2023 buy was Thermo Fisher Scientific: 13,849 shares worth $7.01M.
  • Endurant Capital Management added most to BioMarin Pharmaceuticals in Q3 2023, an estimated $12.1M increase.
  • Endurant Capital Management's biggest Q3 2023 reduction was Cigna, cutting an estimated $5.63M.
  • Endurant Capital Management fully exited Labcorp in Q3 2023, selling an estimated $7.86M.
  • Endurant Capital Management's ten largest holdings make up 57% of its $111M portfolio in Q3 2023.
  • Endurant Capital Management opened 25 new positions and closed 16 in Q3 2023.
  • Endurant Capital Management's portfolio value fell 2.8% quarter-over-quarter to $111M.

Based on Endurant Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.